6 / 28
Why pick the biomarker as the primary endpoint: Summary of Phase I and II atezolizumab data
JE Rosenberg et al. The Lancet 2016, 387, 1909 – 1920
T Powles et al. Nature 2014, 515, 558–562
|
|
6 / 28
6 / 28
Why pick the biomarker as the primary endpoint: Summary of Phase I and II atezolizumab data
JE Rosenberg et al. The Lancet 2016, 387, 1909 – 1920
T Powles et al. Nature 2014, 515, 558–562